Neurologists Describe Childhood Absence Epilepsy as 'Underrecognized' but 'Easily Diagnosed and Treated'
Expanding awareness of Childhood Absence Epilepsy helps early diagnosis and treatment
WASHINGTON, May 6, 2024 /PRNewswire/ -- The subtlety of childhood absence epilepsy (CAE) seizures, coupled with their close association with learning and mental health difficulties, can delay diagnosis despite CAE being one of the most common pediatric syndromes in the United States, according to a new expert-led clinical proceedings paper from the Clinical Neurological Society of America.
Childhood absence epilepsy seizures are brief staring spells with loss of awareness that cannot be interrupted by voice or touch. Seizures can occur multiple times per day. CAE may go undiagnosed or misdiagnosed because it can be mistaken for ADHD or be difficult for parents, teachers and other caregivers to recognize. While CAE usually remits within two years of onset or by early adolescence, the impact on children's social and emotional health can be long term.
Improving awareness of the disease among parents, teachers, health care providers and the community at large;
Increasing understanding of its link to ADHD and other learning and mental health challenges; and
Improving access to diagnosis and treatment.
Expert Panelists:
Katy Lalor, MD (Clinical Proceedings Chair)
Allison Conravey, MD
Sudha Kilaru Kessler, MD
Elaine C. Wirrell, MD
Statement from Katy Lalor, MD, Clinical Proceedings Chair:
"Expanding awareness among the public of CAE is the first step to earlier diagnosis and treatment. And with a greater understanding of CAE's link to ADHD and other learning and mental health challenges, we can reduce the burden of this disease and improve the short-term and long-term outcomes of these children."
The Clinical Neurological Society of America, a non-profit 501(c)(6), is a nationwide organization of neurology clinicians with a mission to improve clinical practice and patient care through education.
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument?
?QOL-B...
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...